Table of Content

Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL TOURETTE SYNDROME DRUG INDUSTRY
2.1 Summary about Tourette Syndrome Drug Industry
2.2 Tourette Syndrome Drug Market Trends
2.2.1 Tourette Syndrome Drug Production & Consumption Trends
2.2.2 Tourette Syndrome Drug Demand Structure Trends
2.3 Tourette Syndrome Drug Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 AZD-5213
4.2.2 CPP-115
4.2.3 Dutetrabenazine ER
4.2.4 Ecopipam Hydrochloride
4.2.5 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Research Center
4.3.2 Hospital
4.3.3 Clinic
4.3.4 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 AZD-5213
5.2.2 CPP-115
5.2.3 Dutetrabenazine ER
5.2.4 Ecopipam Hydrochloride
5.2.5 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Research Center
5.3.2 Hospital
5.3.3 Clinic
5.3.4 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 AZD-5213
6.2.2 CPP-115
6.2.3 Dutetrabenazine ER
6.2.4 Ecopipam Hydrochloride
6.2.5 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Research Center
6.3.2 Hospital
6.3.3 Clinic
6.3.4 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 AZD-5213
7.2.2 CPP-115
7.2.3 Dutetrabenazine ER
7.2.4 Ecopipam Hydrochloride
7.2.5 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Research Center
7.3.2 Hospital
7.3.3 Clinic
7.3.4 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 AZD-5213
8.2.2 CPP-115
8.2.3 Dutetrabenazine ER
8.2.4 Ecopipam Hydrochloride
8.2.5 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Research Center
8.3.2 Hospital
8.3.3 Clinic
8.3.4 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 AZD-5213
9.2.2 CPP-115
9.2.3 Dutetrabenazine ER
9.2.4 Ecopipam Hydrochloride
9.2.5 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Research Center
9.3.2 Hospital
9.3.3 Clinic
9.3.4 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Abide Therapeutics Inc
10.1.2 Catalyst Pharmaceuticals Inc
10.1.3 Neurocrine Biosciences Inc
10.1.4 Psyadon Pharmaceuticals Inc
10.1.5 Reviva Pharmaceuticals Inc
10.1.6 Synchroneuron Inc
10.1.7 Teva Pharmaceutical Industries Ltd
10.1.8 Therapix Biosciences Ltd
10.2 Tourette Syndrome Drug Sales Date of Major Players (2017-2020e)
10.2.1 Abide Therapeutics Inc
10.2.2 Catalyst Pharmaceuticals Inc
10.2.3 Neurocrine Biosciences Inc
10.2.4 Psyadon Pharmaceuticals Inc
10.2.5 Reviva Pharmaceuticals Inc
10.2.6 Synchroneuron Inc
10.2.7 Teva Pharmaceutical Industries Ltd
10.2.8 Therapix Biosciences Ltd
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

List of Figure

List of Table
Table Tourette Syndrome Drug Product Type Overview
Table Tourette Syndrome Drug Product Type Market Share List
Table Tourette Syndrome Drug Product Type of Major Players
Table Brief Introduction of Abide Therapeutics Inc
Table Brief Introduction of Catalyst Pharmaceuticals Inc
Table Brief Introduction of Neurocrine Biosciences Inc
Table Brief Introduction of Psyadon Pharmaceuticals Inc
Table Brief Introduction of Reviva Pharmaceuticals Inc
Table Brief Introduction of Synchroneuron Inc
Table Brief Introduction of Teva Pharmaceutical Industries Ltd
Table Brief Introduction of Therapix Biosciences Ltd
Table Products & Services of Abide Therapeutics Inc
Table Products & Services of Catalyst Pharmaceuticals Inc
Table Products & Services of Neurocrine Biosciences Inc
Table Products & Services of Psyadon Pharmaceuticals Inc
Table Products & Services of Reviva Pharmaceuticals Inc
Table Products & Services of Synchroneuron Inc
Table Products & Services of Teva Pharmaceutical Industries Ltd
Table Products & Services of Therapix Biosciences Ltd
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Tourette Syndrome Drug Market Forecast (Million USD) by Region 2021f-2026f
Table Global Tourette Syndrome Drug Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Tourette Syndrome Drug Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Tourette Syndrome Drug Market Forecast (Million USD) Share by Demand 2021f-2026f